Comparison · NCT00307164-26beecfa
NucleomaxX vs Placebo: Number of Subjects Discontinuing Study Medication
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NucleomaxX vs Placebo: Number of Subjects Discontinuing Study Medication. Trial comparisons, record NCT00307164-26beecfa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00307164-26beecfa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.41 | 0.31 | 0.517 | wilson | |
| Risk in group 2 | 0.415 | 0.314 | 0.523 | wilson | |
| Risk difference, group 1 minus group 2 | -0.005 | -0.152 | 0.142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.988 | 0.686 | 1.42 | log | |
| Odds ratio, group 1 over group 2 | 0.98 | 0.527 | 1.82 | log | |
| Number needed to treat, for one fewer participant with the outcome on NucleomaxX than on Placebo | 200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NucleomaxX | Participants received NucleomaxX for uridine through week 48 | 34 | 83 | OG000 |
| Group 2 | Placebo | Participants received NucleomaxX placebo through week 48 | 34 | 82 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Discontinuing Study Medication
- Description
- Number of eligible subjects who discontinued study medication during the study period.
- Time frame
- Through Week 48
- Population
- Intention to treat analysis based on all subjects who started study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
- NCT number
- NCT00307164
- Phases
- PHASE2, PHASE3
- Conditions
- HIV Infections, Lipoatrophy
- Interventions
- NucleomaxX, NucleomaxX placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2011-10-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00307164?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00307164-26beecfa